Display Settings:

Format

Send to:

Choose Destination

    Diabetes. 2006 Apr;55(4):1011-21.

    CD4+ CD25+ regulatory T-cells inhibit the islet innate immune response and promote islet engraftment.

    Chen D, Zhang N, Fu S, Schröppel B, Guo Q, Garin A, Lira SA, Bromberg JS.

    Department of Gene and Cell Medicine, and Recanati/Miller Transplantation Institute, Mount Sinai School of Medicine, New York, NY 10029-6574, USA.

    Early islet cell loss is a significant problem in clinical islet cell transplantation. Diverse stress stimuli induce innate immune responses in islets that contribute to beta-cell dysfunction, inflammation, and loss. Here, we show that cytokine-stimulated murine islets express multiple inflammatory chemokines that recruit T-cells and thereby impair islet function in vitro and in vivo. Both nonislet ductal and exocrine elements and the individual islet cellular components contribute to this innate immune response. CD4+ CD25+ regulatory T-cells inhibit islet chemokine expression through a cell contact-dependent, soluble factor-independent mechanism and inhibit effector T-cell migration to the islet. Regulatory T-cells can also migrate to stimulated islets. Cotransfer of regulatory T-cells with islets in a transplantation model prevents islet innate immune responses and inflammation and preserves normal architecture and engraftment. Regulatory T-cell inhibition of multiple components of innate immune responses may be a fundamental aspect of their function that influences ischemia-reperfusion injury and adaptive immunity.

    PMID: 16567523 [PubMed - indexed for MEDLINE]

    Supplemental Content

    Click here to read